Company: GenSight Biologics
Job title: Chief Medical Officer
Dr. Taiel completed her doctorate in Medicine with board certified in Ophthalmology from Lariboisiere Saint Louis University, Paris, France, in 1993, and her Associate Professor degree in 1998. Dr Taiel completed her internship at academic Paris hospitals, was an Associate Professor of Ophthalmology, served as an Ophthalmology Department Head, and ran Surgical and Medical Ophthalmology private practice. After 13 years of Ophthalmology public and private practice, Dr Taiel has been engaged in the Pharma Industry for 20 years; she brings extensive experience and expertise in drug clinical development, gene therapy, and medical affairs. She started her carrier at Servier company headquarter, and then worked in Ophthalmology area at Pfizer for several years; she then held international and management positions in various therapeutic areas, including both technical and supervision duties, at Eli Lilly Company for many years. Then, as VP Clinical Development, she led Clinical Development and Operations, to develop antisense oligonucleotides in Inherited Retinal diseases at ProQR Therapeutics. She then moved to GenSight-Biologics in 2018, to supervise the Medical Department and lead Gene Therapy programs in Inherited Retinal and Neuro-Ophthalmology diseases, as the CMO of the company.
Dr. Taiel has authored numerous protocols and articles published in peer reviewed journals, and made critical contributions to successful clinical development and launch of many products. She brings extensive years of experience from both academic medicine and pharma industry.
Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) 2:45 pm
• Examine LHON and its main clinical aspects • Late-stage development of Lumevoq Gene Therapy • Discuss regulatory pathways • Outline key learnings Lumevoq gene therapyRead more
day: Day Two
Panel Discussion: Recognize the Financial Difficulty of Developing Drugs for Targeting Mitochondria & Moving Drugs to the Next Phase 12:00 pm
• Explore the challenges of funding development • Learn how drug developers can inspire and attract companies to invest in their novel development and pipeline • Discover how can the industry come together to overcome the paucity of fundingRead more
day: Day Two